why choose us

First received: December 12, 2022

Clinical Trial: REmission in Membranous Nephropathy International Trial (REMIT)

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Primary Membranous Nephropathy

Study Type: INTERVENTIONAL


Official Title: International, Multi-centre Randomised Clinical Trial of Obinutuzumab Versus Corticosteroid and Cyclophosphamide in Primary Membranous Nephropathy (REMIT Trial).

Brief Summary: REMIT is an investigator-initiated, international, multi-centre, prospective, randomised, open-label, parallel-group trial.A total of 224 adult participants with Primary Membranous Nephropathy (PMN) will be recruited from renal units from Australia, New Zealand Canada, Asia, Europe, United Kingdom, and other countries.Participants will be randomised to receive either corticosteroid and cyclophosphamide or obinutuzumab.The primary outcome is a ranked, composite measure based on (a) efficacy, defined as either…

Read more